|
1
|
Whaley-Connell A, Johnson MS and Sowers
JR: Aldosterone: role in the cardiometabolic syndrome and resistant
hypertension. Prog Cardiovasc Dis. 52:401–409. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Aroor AR, Demarco VG, Jia G, Sun Z,
Nistala R, Meininger GA and Sowers JR: The role of tissue
renin-angiotensin-aldosterone system in the development of
endothelial dysfunction and arterial stiffness. Front Endocrinol
Lausanne: 4. pp. 1612013, View Article : Google Scholar
|
|
3
|
Schiffrin EL and Touyz RM: From bedside to
bench to bedside: role of renin-angiotensin-aldosterone system in
remodeling of resistance arteries in hypertension. Am J Physiol
Heart Circ Physiol. 287:H435–H446. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Touyz RM: The role of angiotensin II in
regulating vascular structural and functional changes in
hypertension. Curr Hypertens Rep. 5:155–164. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stoll M, Steckelings UM, Paul M, Bottari
SP, Metzger R and Unger T: The angiotensin AT2-receptor mediates
inhibition of cell proliferation in coronary endothelial cells. J
Clin Invest. 95:651–657. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sata M and Fukuda D: Crucial role of
renin-angiotensin system in the pathogenesis of atherosclerosis. J
Med Invest. 57:12–25. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hill BG, Dranka BP, Zou L, Chatham JC and
Darley-Usmar VM: Importance of the bioenergetic reserve capacity in
response to cardiomyocyte stress induced by 4-hydroxynonenal.
Biochem J. 424:99–107. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ballinger SW: Mitochondrial dysfunction in
cardiovascular disease. Free Radic Biol Med. 38:1278–1295. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Madamanchi NR and Runge MS: Mitochondrial
dysfunction in atherosclerosis. Circ Res. 100:460–473. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ryan MT and Hoogenraad NJ:
Mitochondrial-nuclear communications. Annu Rev Biochem. 76:701–722.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Picard M, Taivassalo T, Gouspillou G and
Hepple RT: Mitochondria: isolation, structure and function. J
Physiol. 589:4413–4421. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dranka BP, Hill BG and Darley-Usmar VM:
Mitochondrial reserve capacity in endothelial cells: the impact of
nitric oxide and reactive oxygen species. Free Radic Biol Med.
48:905–914. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Davignon J: Beneficial cardiovascular
pleiotropic effects of statins. Circulation. 109(Suppl 1):
III39–III43. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guimarães DA, Rizzi E, Ceron CS, Pinheiro
LC, Gerlach RF and Tanus-Santos JE: Atorvastatin and sildenafil
lower blood pressure and improve endothelial dysfunction, but only
atorvastatin increases vascular stores of nitric oxide in
hypertension. Redox Biol. 1:578–585. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou MS, Tian R, Jaimes EA and Raij L:
Combination therapy of amlodipine and atorvastatin has more
beneficial vascular effects than monotherapy in salt-sensitive
hypertension. Am J Hypertens. 27:873–880. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ma Y, Chen Z, Zou Y and Ge J: Atorvastatin
represses the angiotensin 2-induced oxidative stress and
inflammatory response in dendritic cells via the I3K/Akt/Nrf2
pathway. Oxid Med Cell Longev. 148798:2014. View Article : Google Scholar
|
|
17
|
Chen S, Liu B, Kong D, Li S, Li C, Wang H
and Sun Y: Atorvastatin calcium inhibits phenotypic modulation of
PDGF-BB-induced VSMCs via down-regulation the Akt signaling
pathway. PLoS One. 10:e01225772015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ke N, Wang X, Xu X and Abassi YA: The
xCELLigence system for real-time and label-free monitoring of cell
viability. Methods Mol Biol. 740:33–43. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ma M, Guo X, Chang Y, Li C, Meng X, Li S,
Du ZX, Wang HQ and Sun Y: Advanced glycation end products promote
proliferation and suppress autophagy via reduction of cathepsin D
in rat vascular smooth muscle cells. Mol Cell Biochem. 403:73–83.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li Z, Berk M, McIntyre TM, Gores GJ and
Feldstein AE: The lysosomal-mitochondrial axis in free fatty
acid-induced hepatic lipotoxicity. Hepatology. 47:1495–1503. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gottlieb E, Armour SM, Harris MH and
Thompson CB: Mitochondrial membrane potential regulates matrix
configuration and cytochrome c release during apoptosis. Cell Death
Differ. 10:709–717. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lei T, Guo N, Tan MH and Li YF: Effect of
mouse oocyte vitrification on mitochondrial membrane potential and
distribution. J Huazhong Univ Sci Technolog Med Sci. 34:99–102.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hill BG, Higdon AN, Dranka BP and
Darley-Usmar VM: Regulation of vascular smooth muscle cell
bioenergetic function by protein glutathiolation. Biochim Biophys
Acta. 1797:285–295. 2010. View Article : Google Scholar :
|
|
24
|
Alvarez E, Rodiño-Janeiro BK,
Ucieda-Somoza R and González-Juanatey JR: Pravastatin counteracts
angiotensin II-induced upregulation and activation of NADPH oxidase
at plasma membrane of human endothelial cells. J Cardiovasc
Pharmacol. 55:203–212. 2010. View Article : Google Scholar
|
|
25
|
Ferrick DA, Neilson A and Beeson C:
Advances in measuring cellular bioenergetics using extracellular
flux. Drug Discov Today. 13:268–274. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sansbury BE, Jones SP, Riggs DW,
Darley-Usmar VM and Hill BG: Bioenergetic function in
cardiovascular cells: the importance of the reserve capacity and
its biological regulation. Chem Biol Interact. 191:288–295. 2011.
View Article : Google Scholar :
|
|
27
|
Li P, Guo X, Lei P, Shi S, Luo S and Cheng
X: I3K/Akt/uncoupling protein 2 signaling pathway may be involved
in cell senescence and apoptosis induced by angiotensin II in human
vascular endothelial cells. Mol Biol Rep. 41:6931–6937. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Eelen G, de Zeeuw P, Simons M and
Carmeliet P: Endothelial cell metabolism in normal and diseased
vasculature. Circ Res. 116:1231–1244. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Graham DJ, Staffa JA, Shatin D, Andrade
SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ and
Platt R: Incidence of hospitalized rhabdomyolysis in patients
treated with lipid-lowering drugs. JAMA. 292:2585–2590. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sathasivam S: Statin induced myotoxicity.
Eur J Intern Med. 23:317–324. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mabuchi H, Higashikata T, Kawashiri M,
Katsuda S, Mizuno M, Nohara A, Inazu A, Koizumi J and Kobayashi J:
Reduction of serum ubiquinol-10 and ubiquinone-10 levels by
atorvastatin in hypercholesterolemic patients. J Atheroscler
Thromb. 12:111–119. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vaughan RA, Garcia-Smith R, Bisoffi M,
Conn CA and Trujillo KA: Ubiquinol rescues simvastatin-suppression
of mitochondrial content, function and metabolism: implications for
statin-induced rhabdomyolysis. Eur J Pharmacol. 711:1–9. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mullen PJ, Zahno A, Lindinger P, Maseneni
S, Felser A, Krähenbühl S and Brecht K: Susceptibility to
simvastatin-induced toxicity is partly determined by mitochondrial
respiration and phosphorylation state of Akt. Biochim Biophys Acta.
1813:2079–2087. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Carnicka S, Adameova A, Nemcekova M,
Matejikova J, Pancza D and Ravingerova T: Distinct effects of acute
pretreatment with lipophilic and hydrophilic statins on myocardial
stunning, arrhythmias and lethal injury in the rat heart subjected
to ischemia/reperfusion. Physiol Res. 60:825–830. 2011.PubMed/NCBI
|
